Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease.
rosiglitazone
AVA102672
NCT00348309
Alzheimer's Disease
Phase 3
 
A follow-on study AVA102675 was conducted.
January 2015

Powered by ideaPoint, Inc.